Global Thyroid Cancer Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Thyroid Cancer Diagnostics Market Size

• The global thyroid cancer diagnostics market size was valued at USD 7.92 billion in 2024 and is expected to reach USD 12.35 billion by 2032, at a CAGR of 5.70% during the forecast period
• The market growth is largely fueled by increasing thyroid cancer incidence worldwide and advancements in imaging and molecular diagnostic techniques, enabling earlier and more precise disease detection
• Furthermore, rising awareness among patients and healthcare providers, combined with growing demand for non-invasive, accurate, and efficient diagnostic solutions, is establishing advanced diagnostic platforms as essential tools in oncology. These converging factors are accelerating the adoption of thyroid cancer diagnostics, thereby significantly boosting the industry's growth

Thyroid Cancer Diagnostics Market Analysis

• Thyroid cancer diagnostics, encompassing imaging modalities, fine-needle aspiration biopsies, and molecular testing, are increasingly vital components of modern oncology due to their role in early detection, accurate classification, and effective disease monitoring in both hospital and clinical settings
• The escalating demand for thyroid cancer diagnostics is primarily fueled by the rising global incidence of thyroid malignancies, growing awareness of the importance of early diagnosis, and technological advancements in molecular and imaging-based diagnostic tools
• North America dominated the thyroid cancer diagnostics market with the largest revenue share of 39.2% in 2024, driven by advanced healthcare infrastructure, high screening rates, and a robust presence of diagnostic solution providers, with the U.S. experiencing increased uptake of precision diagnostic tools and next-generation sequencing for thyroid nodule assessment
• Asia-Pacific is expected to be the fastest growing region in the thyroid cancer diagnostics market during the forecast period due to improving healthcare access, rising awareness, and government initiatives for cancer screening
• Imaging test segment dominated the thyroid cancer diagnostics market with a market share of 47% in 2024, driven by its non-invasive nature, diagnostic accuracy, and widespread availability in primary and tertiary healthcare settings

Report Scope and Thyroid Cancer Diagnostics Market Segmentation

Thyroid Cancer Diagnostics Market Trends

“Rising Adoption of Molecular and Genomic Testing for Precision Diagnosis”

• A significant and accelerating trend in the global thyroid cancer diagnostics market is the growing utilization of molecular and genomic testing techniques such as next-generation sequencing (NGS), BRAF mutation analysis, and gene expression classifiers. These advanced methods are significantly improving diagnostic accuracy and enabling more personalized treatment strategies
  • For instance, tests such as ThyroSeq and Afirma Genomic Sequencing Classifier (GSC) are being increasingly adopted to differentiate between benign and malignant thyroid nodules,especially in cases with indeterminate cytology results. These tests reduce unnecessary surgeries and provide patients with more targeted clinical management options.
• Molecular diagnostics offer a deeper understanding of tumor behavior and genetic alterations, enabling oncologists to tailor treatments based on individual patient profiles. The integration of these tools in clinical decision-making supports earlier diagnosis and better prognosis in thyroid cancer cases
• Furthermore, advancements in liquid biopsy technology and biomarker research are driving the development of non-invasive diagnostic methods, offering real-time tumor monitoring and facilitating early relapse detection
• The trend towards personalized medicine and minimally invasive diagnostics is reshaping the thyroid cancer landscape, prompting companies such as Veracyte and Roche Diagnostics to invest in the development of genomic tools with improved sensitivity and specificity
• This shift toward molecular-based diagnostics is not only enhancing patient outcomes but also attracting greater investment and regulatory support, reinforcing the market’s transition from traditional pathology to precision diagnostics

Thyroid Cancer Diagnostics Market Dynamics

Driver

“Increasing Thyroid Cancer Prevalence and Demand for Early Detection”

• The rising global incidence of thyroid cancer, particularly papillary thyroid carcinoma, is a primary driver for the expanding demand for accurate and early diagnostic solutions. Improved awareness, routine screening programs, and advancements in diagnostic imaging have contributed to an increased detection rate
  • For instance, the widespread use of high-resolution ultrasound and fine-needle aspiration biopsy (FNAB) has enabled earlier and more precise identification of suspicious thyroid nodules. Moreover, the adoption of molecular markers in indeterminate FNAB cases has significantly enhanced diagnostic confidence
• Healthcare providers are increasingly prioritizing early detection to reduce overtreatment and improve prognosis, especially as survival rates are strongly correlated with early-stage diagnosis. This emphasis is fostering growth in diagnostic infrastructure and driving technological innovations in the sector
• In addition, initiatives from health agencies and oncology organizations aimed at early screening and awareness campaigns are fueling patient engagement, leading to increased diagnostic testing volumes across both developed and developing nations
• As diagnostic platforms become more accessible and refined, the market is witnessing a growing shift towards preventive oncology and personalized care, further boosting the demand for reliable thyroid cancer diagnostic solutions

Restraint/Challenge

“High Diagnostic Costs and Limited Access to Advanced Testing in Developing Regions”

• The high cost of molecular and genomic thyroid cancer diagnostic tests remains a major barrier to widespread adoption, particularly in low- and middle-income countries where healthcare resources are limited and insurance coverage for such tests is often lacking
  • For instance, advanced tests such as ThyroSeq or Afirma GSC may not be readily available or affordable outside of specialized oncology centers, restricting access for patients in rural or underserved areas
• Furthermore, disparities in diagnostic infrastructure, shortage of skilled personnel, and limited availability of laboratory equipment continue to impede adoption in regions with weak healthcare systems
• Regulatory complexities, reimbursement challenges, and slow integration of novel diagnostic approaches into standard clinical guidelines also hinder market penetration, especially for newer molecular diagnostics
• To overcome these challenges, manufacturers are focusing on developing cost-effective solutions, expanding tele-diagnostic services, and partnering with governments and NGOs to improve diagnostic access. However, bridging the gap between advanced and accessible diagnostics remains essential for ensuring equitable thyroid cancer care globally

Thyroid Cancer Diagnostics Market Scope

The market is segmented on the basis of product type, test type, cancer type, stages, age group, end user, and distribution channel.

• By Product Type

On the basis of product type, the thyroid cancer diagnostics market is segmented into instruments and consumables and accessories. The consumables and accessories segment dominated the market with the largest market revenue share in 2024, driven by the frequent and recurring use of biopsy kits, reagents, and assay kits in diagnostic procedures. These items are essential across multiple testing formats and offer consistent demand across both public and private healthcare institutions.

The instruments segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by technological innovations in ultrasound, CT, and MRI devices, as well as automated diagnostic platforms. The push for modernized diagnostic infrastructure and early-stage cancer detection tools is supporting rapid growth in this segment across hospitals and advanced labs.

• By Test Type

On the basis of test type, the thyroid cancer diagnostics market is segmented into imaging test, biopsy, blood test, and others. The imaging test segment dominated the market with the largest market revenue share of 47% in 2024, supported by the use of ultrasound and radioactive iodine scans for initial assessment and follow-up of thyroid nodules. Imaging is the primary diagnostic tool due to its non-invasive nature and high accuracy in detecting abnormalities.

The biopsy segment is expected to witness the fastest CAGR from 2025 to 2032, driven by the rising utilization of fine-needle aspiration biopsy (FNAB) and molecular testing methods to improve diagnostic specificity and reduce unnecessary surgeries.

• By Cancer Type

On the basis of cancer type, the thyroid cancer diagnostics market is segmented into papillary carcinoma, follicular carcinoma, and others. The papillary carcinoma segment held the largest market revenue share in 2024, driven by its high prevalence and favorable prognosis. Routine screening programs and high detection rates of this cancer subtype support its leading position in the market.

The follicular carcinoma segment is anticipated to register steady growth from 2025 to 2032, supported by the development of advanced diagnostic tools that differentiate follicular patterns and support early clinical decision-making.

• By Stages

On the basis of stages, the thyroid cancer diagnostics market is segmented into Stage I, Stage II, Stage III, and Stage IV. The Stage I segment held the largest market share in 2024, attributed to the increased rate of early detection through screening and improved public awareness, especially in developed countries. This stage represents the majority of initial diagnoses, creating sustained demand for imaging and pathology tests.

The Stage IV segment is expected to grow at a fastest rate during forecast period, due to the increasing need for advanced imaging, molecular profiling, and monitoring tools for metastatic or aggressive thyroid cancer cases.

• By Age Group

On the basis of age group, the thyroid cancer diagnostics market is segmented into below 21, 21–29, 30–65, and 65 and above. The 30–65 age group dominated the market with the largest revenue share in 2024, as thyroid cancer is most frequently diagnosed in middle-aged adults, particularly females. This age group has higher health-seeking behavior and access to diagnostic services, driving consistent demand.

The 65 and above segment is projected to witness the fastest growth during the forecast period, supported by rising thyroid disorder cases and increased diagnostic interventions among elderly populations.

• By End User

On the basis of distribution channel, the thyroid cancer diagnostics market is segmented into direct tender and retail sales. The direct tender segment dominated the market with the largest market revenue share in 2024, due to bulk procurement by public hospitals and diagnostic labs for diagnostic kits, reagents, and equipment under long-term contracts and government-supported programs.

The retail sales segment is anticipated to grow at the fastest rate during the forecast period, supported by the emergence of online pharmacies, direct-to-consumer diagnostic test kits, and the rising preference for decentralized and home-based diagnostic testing options.

• By Distribution Channel

On the basis of distribution channel, the thyroid cancer diagnostics market is segmented into direct tender and retail sales. The direct tender segment dominated the market with the largest market revenue share in 2024, due to bulk procurement by public hospitals and diagnostic labs for diagnostic kits, reagents, and equipment under long-term contracts and government-supported programs.

The retail sales segment is anticipated to grow at the fastest rate during the forecast period, supported by the emergence of online pharmacies, direct-to-consumer diagnostic test kits, and the rising preference for decentralized and home-based diagnostic testing options.

Thyroid Cancer Diagnostics Market Regional Analysis

• North America dominated the thyroid cancer diagnostics market with the largest revenue share of 39.2% in 2024, driven by advanced healthcare infrastructure, high screening rates, and a robust presence of diagnostic solution providers, with the U.S. experiencing increased uptake of precision diagnostic tools and next-generation sequencing for thyroid nodule assessment
• Consumers and healthcare providers in the region prioritize early detection, precision diagnostics, and comprehensive cancer care, leading to widespread use of technologies such as fine-needle aspiration biopsies, ultrasound, and gene expression profiling
• This strong market presence is further supported by favorable reimbursement policies, robust healthcare spending, and ongoing investments in cancer research and innovation across the United States and Canada

U.S. Thyroid Cancer Diagnostics Market Insight

The U.S. thyroid cancer diagnostics market captured the largest revenue share of 79% in 2024 within North America, fueled by the country’s high thyroid cancer screening rates, advanced healthcare infrastructure, and widespread adoption of molecular diagnostics. Increased awareness of thyroid health and early detection, combined with the strong presence of diagnostic device manufacturers and genomic testing providers, continues to drive market growth. Moreover, the integration of precision medicine and AI-based diagnostic tools is enhancing diagnostic accuracy and clinical decision-making across hospitals and diagnostic laboratories.

Europe Thyroid Cancer Diagnostics Market Insight

The Europe thyroid cancer diagnostics market is projected to grow at a steady CAGR throughout the forecast period, primarily driven by rising cancer awareness, structured cancer screening programs, and investments in healthcare modernization. Government support and funding for early cancer detection, coupled with rising adoption of advanced imaging and biopsy techniques, are fueling market growth. The demand for accurate diagnostic tools is increasing across both public and private healthcare sectors, with a shift toward molecular diagnostics to support risk stratification and personalized treatment planning.

U.K. Thyroid Cancer Diagnostics Market Insight

The U.K. thyroid cancer diagnostics market is anticipated to grow at a notable CAGR during the forecast period, driven by increasing public health awareness and improvements in diagnostic imaging technologies. The National Health Service (NHS) emphasizes early diagnosis and streamlined care pathways, boosting the adoption of ultrasound, FNAB, and genomic testing. In addition, collaborations with academic research centers and clinical trials involving novel biomarkers are enhancing innovation and expanding diagnostic options in the U.K.

Germany Thyroid Cancer Diagnostics Market Insight

The Germany thyroid cancer diagnostics market is expected to expand at a substantial CAGR over the forecast period, fueled by the country’s robust healthcare infrastructure and commitment to medical innovation. Germany’s high diagnostic standards and early cancer detection initiatives are promoting the widespread use of imaging and molecular diagnostics. Rising demand for precision diagnostics and real-time monitoring tools is supporting the growth of advanced testing methods, especially within urban medical centers and cancer institutes.

Asia-Pacific Thyroid Cancer Diagnostics Market Insight

The Asia-Pacific thyroid cancer diagnostics market is poised to grow at the fastest CAGR during the forecast period of 2025 to 2032, driven by rising cancer incidence, increasing awareness of thyroid health, and expanding healthcare access in countries such as China, Japan, and India. Government-led cancer screening programs, growing urban populations, and rising investment in diagnostic infrastructure are accelerating adoption. As affordability and accessibility of diagnostic tools improve, the region is witnessing increased uptake of both conventional and molecular testing.

Japan Thyroid Cancer Diagnostics Market Insight

The Japan thyroid cancer diagnostics market is gaining momentum due to the country’s strong emphasis on preventive care, advanced medical technology, and increasing incidence of thyroid-related conditions. The integration of AI-enhanced imaging and genetic testing into routine diagnostics is elevating the standard of care. Japan’s aging population and rising focus on early detection of cancers are further supporting the widespread use of thyroid screening programs and non-invasive diagnostic solutions.

India Thyroid Cancer Diagnostics Market Insight

The India thyroid cancer diagnostics market accounted for the largest market revenue share in Asia Pacific in 2024, attributed to the growing prevalence of thyroid disorders, increasing public health initiatives, and rapid improvements in diagnostic infrastructure. With a surge in awareness about early cancer detection and rising healthcare spending, both public and private facilities are expanding diagnostic capabilities. Affordable testing options and government-backed health programs are facilitating broader access, while the emergence of regional diagnostic players is boosting market penetration in urban and semi-urban areas.

Thyroid Cancer Diagnostics Market Share

The thyroid cancer diagnostics industry is primarily led by well-established companies, including:

• Canon Inc. (Japan)
• FUJIFILM Holdings Corporation (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Quest Diagnostics Incorporated (U.S.)
• Illumina (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Thermo Fisher Scientific Inc. (U.S.)
• Siemens Healthcare GmbH (Germany)
• Abbott (U.S.)
• General Electric Company (U.S.)
• BD (U.S.)
• QIAGEN (Netherlands)
• DIASORIN S.P.A. (Italy)
• Merck KGaA (Germany)
• Hologic (U.S.)
• Myriad Genetics Inc. (U.S.)
• BIOMERIEUX (France)
• FONAR Corp. (U.S.)
• Time Medical Holding (Hong Kong)
• PlexBio (Taiwan)
• MinFound Medical Systems Co., Ltd (China)
• Medonica Co. LTD (South Korea)
• Beijing O&D Biotech Co., Ltd. (China)
• SternMed GmbH (Germany)

What are the Recent Developments in Global Thyroid Cancer Diagnostics Market?

• In April 2024, Roche Diagnostics announced the launch of a next-generation immunohistochemistry (IHC) assay designed to improve the accuracy of thyroid cancer subtyping. The new assay, integrated with Roche’s advanced diagnostic platform, aids pathologists in identifying tumor origin and supports personalized treatment planning. This development highlights Roche’s commitment to advancing cancer diagnostics through precision and automation technologies tailored for clinical settings
• In March 2024, Veracyte, Inc., a leader in genomic diagnostics, expanded access to its Afirma Genomic Sequencing Classifier (GSC) by partnering with key laboratory networks across Europe and Asia. This move is aimed at enhancing the availability of high-accuracy molecular diagnostics for indeterminate thyroid nodules globally. The expansion reinforces Veracyte’s mission to reduce unnecessary surgeries and improve diagnostic clarity through genomic innovation
• In February 2024, Siemens Healthineers introduced an upgraded version of its ultrasound imaging system, specifically optimized for thyroid cancer detection. The system features enhanced Doppler sensitivity and real-time elastography, allowing for more accurate characterization of thyroid nodules. This advancement supports clinicians in non-invasively assessing malignancy risk and underlines Siemens’ focus on innovation in diagnostic imaging
• In January 2024, Thermo Fisher Scientific announced a strategic collaboration with leading cancer research institutes to develop novel liquid biopsy assays for early detection and monitoring of thyroid cancers. The initiative leverages Thermo Fisher’s expertise in next-generation sequencing and aims to provide minimally invasive alternatives for patient management, emphasizing the growing trend toward precision oncology and real-time monitoring
• In December 2023, BioReference Laboratories launched a comprehensive thyroid cancer diagnostic panel combining molecular markers, imaging analysis, and clinical decision support tools. Designed to improve diagnostic workflows in hospital and outpatient settings, this panel reflects the increasing demand for integrated, multi-modal diagnostic solutions in endocrine oncology

SKU-56963